Allstate to Present at Sanford C. Bernstein Investor Conference
Get Alerts ALL Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1.7%
EPS Growth %: -39.4%
Join SI Premium – FREE
NORTHBROOK, Ill., May 12, 2015 /PRNewswire/ -- The Allstate Corporation (NYSE: ALL) announced that Thomas J. Wilson, its chairman and chief executive officer, will present at the Sanford C. Bernstein 31st Annual Strategic Decisions Conference at 2 p.m. Eastern Time on Thursday, May 28. The conference is being held at the Waldorf-Astoria in New York.
An audio webcast of the presentation can be accessed at www.allstateinvestors.com. For those unable to hear the live event, a webcast replay will be posted on the investor relations and executive speeches sections of the company's website shortly after the presentation ends.
The Allstate Corporation (NYSE: ALL) is the nation's largest publicly held personal lines insurer, protecting approximately 16 million households from life's uncertainties through auto, home, life and other insurance offered through its Allstate, Esurance, Encompass and Answer Financial brand names. Allstate is widely known through the slogan "You're In Good Hands With Allstate®." The Allstate brand's network of small businesses offers auto, home, life and retirement products and services to customers in the United States and Canada.
Financial information, including material announcements about The Allstate Corporation, is routinely posted on www.allstateinvestors.com.
Logo - http://photos.prnewswire.com/prnh/20130404/MM88193-b
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/allstate-to-present-at-sanford-c-bernstein-investor-conference-300081267.html
SOURCE The Allstate Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TRON Price Prediction: $23M Revenue Report Beats ETH and SOL Combined as Remittix Plans 41 More Fiat Currencies
- The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
- Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Sanford C. BernsteinSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share